Volume of breast milk at the latest time measured (mL) ( · increasing breast milk production in mothers of non‐hospitalised term infants
1 finding from 1 review
Adverse effects for the infant or mother · increasing breast milk production in mothers of non‐hospitalised term infants
1 finding from 1 review
Risk of HAE attacks (during · children or adults with Types I or II HAE
Avoralstat showed no clear difference in risk of HAE attacks (during compared with placebo (moderate certainty).
1 finding from 1 review
Change in number of HAE attacks (per week) · children or adults with Types I or II HAE
1 finding from 1 review
Mortality (during · children or adults with Types I or II HAE
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (during · children or adults with Types I or II HAE
It is very uncertain whether avoralstat changes serious adverse events (during compared with placebo (very low certainty).
1 finding from 1 review
Quality of lifeAngioedema Quality of Life scale (lower score is better)(during · children or adults with Types I or II HAE
1 finding from 1 review
Disability (any validated scale) (during · children or adults with Types I or II HAE
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (during · children or adults with Types I or II HAE
Avoralstat showed no clear difference in adverse events (during compared with placebo (low certainty).
1 finding from 1 review
Non pelvic pain · women undergoing outpatient hysteroscopy
It is very uncertain whether oral NSAID changes non pelvic pain compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Allergic reaction · women undergoing outpatient hysteroscopy
It is very uncertain whether oral NSAID changes allergic reaction compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · women undergoing outpatient hysteroscopy
1 finding from 1 review
Pain score within 30 min of procedure · women undergoing outpatient hysteroscopy
1 finding from 1 review
Pain score more than 30 min after procedure · women undergoing outpatient hysteroscopy
1 finding from 1 review
Vasovagal reaction · women undergoing outpatient hysteroscopy
It is very uncertain whether oral NSAID changes vasovagal reaction compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · Patients with osteoarthritis of the knee or hip
Oral or transdermal opioids showed no clear difference in pain intensity Various pain scales. (median compared with placebo (high certainty).
1 finding from 1 review
Function Various validated function scales. · Patients with osteoarthritis of the knee or hip
Oral or transdermal opioids showed no clear difference in function Various validated function scales. (median compared with placebo (high certainty).
1 finding from 1 review
Adverse events as N of participants with at least one adverse event objective · Patients with osteoarthritis of the knee or hip
Oral or transdermal opioids probably leads to higher number of participants experiencing any adverse event (median compared with placebo (moderate certainty).
1 finding from 1 review
Number of patients who withdrew because of adverse events · Patients with osteoarthritis of the knee or hip
Oral or transdermal opioids leads to higher number of participants who withdrew because of adverse events (median compared with placebo (high certainty).
1 finding from 1 review
Number of participants experiencing any serious adverse events · Patients with osteoarthritis of the knee or hip
Oral or transdermal opioids showed no clear difference in number of participants experiencing any serious adverse event (median compared with placebo (low certainty).
1 finding from 1 review